Search

Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2 ± 21.9 months) with IH and 45 healthy controls (mean age 21.8 ± 15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay. Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80 ± 4.07 pg/mL vs. 5.66 ± 4.34 pg/mL, 281.10 ± 84.12 pg/mL vs. 234.19 ± 75.38 pg/mL, 1196.99 ± 389.34 pg/mL vs. 996.99 ± 349.16 pg/mL, respectively, p = 0.026, p = 0.030, and p = 0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69 ± 3.94 pg/mL vs. 5.66 ± 4.34 pg/mL, 289.94 ± 83.18 pg/mL vs. 234.19 ± 75.38 pg/mL, 1276.22 ± 388.24 pg/mL vs. 996.99 ± 349.16 pg/mL, respectively, p = 0.017, p = 0.022, and p = 0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly. Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers. [ABSTRACT FROM AUTHOR]